Big Pharma's Uphill 2013 Battle

Big pharma knew it faced an uphill battle when 2012 began. Even drug pipelines stocked full of potential couldn't completely mitigate the patent cliff as several blockbusters lost exclusivity. In fact, generics funneled an estimated $26 billion away from brand name drugs in 2012 alone. Now that the year is over and earnings are in, what can investors learn by taking a big picture view of the industry?   

The following big pharma companies did quite well in softening their fall over the patent cliff.

 

Bristol Myers Squibb (NYSE: BMY  )

Johnson & Johnson (NYSE: JNJ  )

Merck (NYSE: MRK  )

Pfizer (NYSE: PFE  )

Novartis (NYSE: NVS  )

2011 EPS

$2.16

$3.49

$2.02

$1.27

$5.57

2012 EPS

$1.16

$3.86

$2.16

$1.94

$5.25

% Difference

(46.3%)

10.6%

6.9%

52.8%

(6.1%)

2011 Worldwide Pharma Sales

$21.24 billion

$24.37 billion

$41.29 billion

$14.14 billion

$32.5 billion

2012 Worldwide Pharma Sales

$17.62 billion

$25.35 billion

$40.60 billion

$12.89 billion

$32.2 billion

% Difference

(17%)

4%

(1.7%)

(8.8%)

(1%)

Sources: Company earnings releases (unaudited).

While Bristol and Pfizer saw the largest drops in revenue it is important to note that they lost exclusivity for two of the most successful drugs ever: Plavix (Bristol) and Lipitor (Pfizer). If you remove Plavix and Avapro/Avalide from the equation for Bristol, then 2012 pharma sales grew 9.4% over 2011. Similarly, Pfizer saw sales from its product lineup grow 1.4% without Lipitor. This growth may never replace the lost revenue from Plavix and Lipitor, but it is a crucial first step toward the future.  

Combatting the patent cliff
The industry is looking to put the worst of the patent cliff behind it, but it will need to make it through 2013 first when an estimated $35 billion of brand name sales will be lost to generic competition. While this group lost exclusivity for some of the top branded pharmaceuticals in markets worldwide, the worst of the damage appears to have passed. First, let's look at a list of brand names that slid in 2012 and are likely to slide further in 2013:   

Company

Drug

2011 Sales (millions)

2012 Sales (millions), % difference

Johnson & Johnson

Doxil

$402

$83 (79%)

Pfizer

Lipitor

$1,999

$584 (71%)

Bristol-Myers Squibb

Plavix

$7,087

$2,547 (64%)

Bristol

Avapro/Avalide

$952

$503 (47%)

Merck

Singulair

$5,479

$3,853 (30%)

Merck

Cozaar/Hyzaar

$1,663

$1,284 (23%)

Merck

Remicade

$2,667

$2,076 (22%)

Johnson & Johnson

Procrit

$1,623

$1,462 (10%)

Sources: Company earnings releases (unaudited).

Several of the blockbusters listed above still had noteworthy sales because they retained exclusivity in one or more key markets. That won't last forever, which makes the next list even more important. Here is a table of key drugs with upward momentum:

Company

Drug

2011 Sales (millions)

2012 Sales (millions), % difference

Johnson & Johnson

Zytiga

$301

$961; 219%

Novartis

Gilenya

$486

$1,200; 147%

Bristol-Myers Squibb

Yervoy

$360

$706; 96%

Novartis

Afinitor

$431

$797; 85%

Bristol-Myers Squibb

Onglyza

$473

$709; 50%

Johnson & Johnson

Simponi

$410

$607; 48%

Novartis

Tasigna

$694

$1,000; 44%

Novartis

Galvus

$636

$910; 43%

Johnson & Johnson

Stelara

$738

$1,025; 39%

Merck

Gardasil

$1,209

$1,631; 35%

Merck

Januvia

$3,324

$4,086; 23%

Novartis

Lucentis

$1,967

$2,499; 22%

Merck

Janumet

$1,363

$1,659; 22%

Pfizer

Lyrica

$998

$1,132; 13%

Johnson & Johnson

Remicade

$5,492

$6,139; 12%

Sources: Company earnings releases (unaudited).

You'll notice that Johnson & Johnson, Novartis, and Merck appear multiple times on both lists, which can be attributed to early starts in combating the patent cliff. Regarding the above tables, key approvals in the last several years allowed J&J growth drugs to offset declining drugs with a net $1.31 billion in sales.

Merck had a more difficult time replacing Singulair revenue, but still has impressive growth to look forward to in several areas. Diabetes drugs Januvia and Janumet raked in $5.75 billion in 2012, while HPV vaccine Gardasil generated $1.63 billion.

Despite putting up impressive growth for several key drugs and gaining 17 major approvals, Novartis expects 2013 sales to be in line with 2012 totals. The company is preparing for up to $3.5 billion in generic competition this year -- most of which will eat away at the dominance of blood-pressure blockbuster Diovan. If that doesn't sum up the patent cliff struggles facing the industry, then I don't know what does.  

Emerging blockbusters?
We may have to lower the bar on blockbusters or even entertain the possibility that chasing home-run drugs is no longer the best strategy. Nevertheless, diabetes drugs remain big for big pharma. Although Merck's Januvia and Janumet stole the show, Novartis' Galvus climbed 43% to $910 million in sales while Bristol's Onglyza notched a 50% increase. Onglyza in particular will have to grow quickly to make its mark before losing exclusivity in 2014.   

Growth in the diabetes market is nothing compared to Bristol's outlook for melanoma drug Yervoy, which some analysts expect to bring in over $2 billion in peak sales. That figure should only increase as trials for new applications progress, including a promising combination with Roche's vemurafenib.

However, as the tables above illustrate, with every bright spot comes a headache. Bristol's Abilify, which brought in $2.83 billion in sales last year, loses total exclusivity in the beginning of 2014.  

Biologic moat remains strong
It may not be obvious from table above, but four of the ten drugs are biologics (Yervoy, Simponi, Stelara, Remicade) that work by stimulating a patient's immune system. If you've had your coffee, then you'll notice that Remicade was a big loser for Merck and a big winner for Johnson & Johnson. The difference lies in world market rights for each company. Still, you may be wondering how two companies can market the same drug to the tune of billions in annual sales.

Biological manufacturing is a very difficult and expensive part of drug development that is heavily scrutinized by the Food and Drug Administration. The high cost of manufacturing keeps the prices of generic biologics, or biosimilars, much higher than their small molecule counterparts. This allows non-exclusive biologics to maintain sizable market share even when competition arises.

Foolish bottom line
Loss of exclusivity will continue to plague the industry for the next several years. Merck's Temodar, which had sales of $1.85 billion since 2011, will lose exclusivity this August. That's only one of 190 drugs losing some form of exclusivity between 2012 and 2013. The severity of the cliff becomes clear when you consider that only 39 new drugs were approved last year. Therefore, it is important for investors to keep a watchful eye on current product lineups and pipelines.  

One company facing some recent stumbles in with its pipeline is Merck. Will this pharma giant crumble under its own weight, or will it continue to its blue-chip ways for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2237386, ~/Articles/ArticleHandler.aspx, 4/18/2014 2:58:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement